CN109700944A - 治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 - Google Patents
治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 Download PDFInfo
- Publication number
- CN109700944A CN109700944A CN201910197313.3A CN201910197313A CN109700944A CN 109700944 A CN109700944 A CN 109700944A CN 201910197313 A CN201910197313 A CN 201910197313A CN 109700944 A CN109700944 A CN 109700944A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- tea
- gout
- hyperlipidemia
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 30
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 30
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 30
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 29
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 27
- 201000005569 Gout Diseases 0.000 title claims abstract description 26
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000006071 cream Substances 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 26
- 235000013361 beverage Nutrition 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 22
- 235000013616 tea Nutrition 0.000 claims abstract description 19
- 241001122767 Theaceae Species 0.000 claims abstract description 18
- 241001328788 Camellia nitidissima Species 0.000 claims abstract description 15
- 241000234435 Lilium Species 0.000 claims abstract description 15
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 15
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 12
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 12
- 241001646834 Mesona Species 0.000 claims abstract description 12
- 244000197580 Poria cocos Species 0.000 claims abstract description 12
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 12
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 235000015895 biscuits Nutrition 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 12
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 10
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 7
- 235000009508 confectionery Nutrition 0.000 claims abstract description 7
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 6
- 238000012216 screening Methods 0.000 claims abstract description 4
- 240000002045 Guettarda speciosa Species 0.000 claims abstract 4
- 230000008901 benefit Effects 0.000 claims description 20
- 238000002137 ultrasound extraction Methods 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 3
- 239000011425 bamboo Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 9
- 210000002381 plasma Anatomy 0.000 abstract description 7
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 abstract description 5
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 20
- 230000006870 function Effects 0.000 description 16
- 241001247821 Ziziphus Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 244000061520 Angelica archangelica Species 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 8
- 230000004089 microcirculation Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003836 peripheral circulation Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 244000058084 Aegle marmelos Species 0.000 description 2
- 235000003930 Aegle marmelos Nutrition 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000002918 waste heat Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000004302 Microvascular Angina Diseases 0.000 description 1
- 208000026018 Microvascular coronary artery disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 240000002014 Phyllostachys nigra var. henonis Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical group CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001906 first metatarsal bone Anatomy 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法,药材为大枣、桃仁、普洱茶、金花茶、葛根、茯苓、百合、淡竹叶、山楂、枸杞子、仙草、决明子、白芷、甘草,其重量比为100:90~110:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12,制备方法为:将以上食材筛选放入提取锅内,在60度温度下超声波提取两次,一次120分钟,过滤去渣、低温浓缩、冷冻成干膏,并粉碎成细粉,制作成压片糖果或固体饮料、液体饮料、茶膏、饼干、泡腾片、胶囊等,服用后,可降低血浆中的尿酸钠含量,降低血清总胆固醇,降低血清三酰甘油,预防脂肪肝、高脂血症。
Description
技术领域
本发明涉及一种药物及制备法,特别涉及一种治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法,属于中药领域。
背景技术
随着人们生活水平的提高与生活方式的改变,高尿酸血症、痛风、脂肪肝、高脂血症的发病率逐年升高。
高尿酸血症是痛风的发病基础,尿酸盐在机体组织中沉积下来造成损害才出现痛风,尿酸是血浆中非蛋白氮的成分之一,主要来源于机体内细胞核蛋白嘌呤碱分解代谢产生。如果体内产生过多来不及排泄或者尿酸排泄机制退化,则体内尿酸滞留过多,当血液尿酸浓度大于7毫克/分升,导致人体体液变酸,将会影响人体细胞的正常功能,引起高尿酸血症。
高尿酸血症不仅是单一常见的代谢性疾病,血中尿酸水平增高会影响血管内皮,导致内皮释放一氧化氮(NO)下降,血管收缩,血压升高,同时肾脏血管收缩,肾小球滤过率下降,从而使血压升高。同时高尿酸还可激活肾素-血管紧张素(RAS)系统,诱导盐敏感,加速动脉粥样硬化。
痛风是一种常见且复杂的关节炎类型,痛风患者经常会在夜晚出现突然性的关节疼,发病急,关节部位出现严重的疼痛、水肿、红肿和炎症,最常发病的关节是大脚趾(医学术语:第一跖骨),还常见于手部的关节、膝盖、肘部等。痛风是一种单钠尿酸盐(MSU)沉积所致的晶体相关性关节病,与嘌呤代谢紊乱及(或)尿酸排泄减少所致的高尿酸血症直接相关,属代谢性风湿病范畴。
痛风常伴发高尿酸血症、高脂血症、高血压病、糖尿病、动脉硬化及冠心病等症状出现。
脂肪肝是指由于各种原因引起的肝细胞内脂肪堆积过多的病变,是一种常见的肝脏病理改变,而非一种独立的疾病。如果肝内脂肪蓄积太多,超过肝重量的5%或在组织学上肝细胞50%以上有脂肪变性时,就可称为脂肪肝。
高脂血症可分为原发性和继发性两类,原发性与先天性和遗传有关,继发性多发生于代谢性紊乱疾病,高脂血症与年龄、性别、季节、饮酒、吸烟、饮食、体力活动、精神紧张、情绪活动等有关。高脂血症的临床表现主要是脂质在真皮内沉积所引起引起的。
引起高尿酸血症、痛风、脂肪肝、高脂血症的主要原因与生活水平与生活方式有这很大的关系,高尿酸血症、痛风、脂肪肝、高脂血症是临床常见的病症,特别是中老年人常见的疾病,由于这些疾病常常会伴随着脉粥样硬化、心肌梗塞、脑梗塞、高血压等并发症,甚至会出现猝死,为了防止这些疾病的发生,除了加强体育锻炼、注意饮食结构之外,还需要进行药物治疗。
发明内容
针对生活水平提高带来的高尿酸血症、痛风、脂肪肝、高脂血症等症状,本发明提供一种治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法,其目的是通过服用这种中药,提高自身免疫能力,提高抑制血液凝固功效,改善脑微循环和外周循环,降低血浆中的尿酸钠含量,降低血清总胆固醇、LDL胆固醇浓度,降低血清三酰甘油,防止动脉粥样硬化,降低高脂血症引发的心脑血管引起的疾病以及糖尿病、高血压、脂肪肝等的疾病,避免突发性中风、心肌梗死、心脏猝死等发生,延长寿命。
本发明的技术方案是:治疗高尿酸血症痛风脂肪肝高脂血症的药物 ,所述药物原料包括大枣、桃仁、普洱茶、金花茶、葛根、茯苓、百合、淡竹叶、山楂、枸杞子、仙草、决明子、白芷、甘草,大枣与其他药物的重量比为:大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12。
治疗高尿酸血症痛风脂肪肝高脂血症药物的制备方法,超声波提取锅、管道离心机以及冷冻干燥机、双效真空浓缩器设备,所述制备方法包括以下步骤:
根据超声波提取锅的处理量,按照大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12的重量比分别称取上述药物原料重量;
2) 将以上药物原料筛选干净放入超声波提取锅内,在超声波提取锅内加入10倍于药物原料的水;
3)提取时,超声波提取锅控温50-65℃,超声波提取两次,每次超声波提取时间为120分钟,在常压下提取;
4)利用管道离心机过滤去渣;
5)提取液用双效真空浓缩器在低温真空浓缩成稠膏;
6)利用冷冻干燥机在-40℃的温度下,将浓缩稠膏降温,冷冻成干膏;
7)将干膏粉碎成80目细粉;
8)将细粉制作成多种形态的药物;
进一步,所述多种形态包括固体饮料、饼干、袋泡茶、液体饮料、泡腾片或胶囊;
进一步,所述压片糖果、茶膏、袋泡茶、胶囊内为纯中药萃取物;
进一步,所述固体饮料、饼干中均匀混合有辅料,所述辅料麦芽糊精,麦芽糊精与干膏细粉的重量比为1:1;
进一步,所述泡腾片中,中药萃取物干膏细粉占40%,柠檬酸25%,碳酸氢钠35%;
进一步,所述液体饮料内添加有10倍于干膏细粉重量的饮用水;
进一步,所述固体饮料、饼干、袋泡茶、液体饮料、泡腾片或胶囊的最小包装中含有的干膏细粉相同。
本发明具有的积极效果为:通过服用这种中药,能够补中益气,健脾养胃、益精强志、活血化瘀、扩张血管,降低多种致病病菌的活性,提高血管中的血流量,增强血管弹性、清理血液垃圾,减轻体内重金属毒素,提高抵抗抗辐射能力,提高身体抗过敏能力、增强人体器官功能,减少西药带来的副作用,增强抵抗各种病毒的能力,提高自身免疫能力,降低血管血流阻力,减少心肌耗氧量,提高心肌工作效率,提高抑制血液凝固功效,改善脑微循环和外周循环,促进和增强单核细胞系统和吞噬功能,降低血浆中的尿酸钠含量,降低血清总胆固醇、LDL胆固醇浓度、降低血清三酰甘油,防止动脉粥样硬化,能抑制脂肪在肝细胞内沉积、促进肝细胞新生的作用,可降低高脂血症引发的心脑血管引起的疾病以及糖尿病、高血压、脂肪肝等的疾病,避免突发性中风、心肌梗死、心脏猝死等发生,延长寿命。
在制备过程中,通过利用超声波萃取,能够利用物理作用、溶剂和样品之间空化作用能促使植物细胞组织破壁或变形,溶质的质点间的振动、加速度冲击、声压剪切等效应力加强,使物料形成局部点的极端高温高压使大体积的中药材可充分接触到超声波探头,加速原料药内有效成分的均匀析出,提高目标物从固相转移到液相的传质速率;在50℃-65℃水温超声波强化萃取,无水煮高温,不破坏中药材中某些具有热不稳定,易水解或氧化特性的药效成份。
附图说明
图1 从原料到干膏细粉的工艺流程图。
标号说明:11-电子秤、12-振动筛、13-热回流机组、14-管道离心机、15-储液罐、16-双效真空浓缩器、17-真空干燥机、18-冷冻干燥机、19-粉碎机。
具体实施方式
本发明的技术方案是治疗高尿酸血症痛风脂肪肝高脂血症的药物,所述药物原料即:药材包括大枣、桃仁、普洱茶、金花茶、葛根、茯苓、百合、淡竹叶、山楂、枸杞子、仙草、决明子、白芷、甘草,大枣与其他药物的重量比为:大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12。
在本实施例中,各种重要在本发明中具有的功效和治疗效果如下:
大枣:红枣含有蛋白质、糖类、有机酸、维生素A、维生素C 、多种微量钙以及氨基酸等丰富的营养成份,红枣能促进白细胞的生成,降低血清胆固醇,提高血清白蛋白 ,保护肝脏,红枣中的维生素C,能使体内多余的胆固醇转变为胆汁酸,降低患病风险,红枣还能够软化血管,从而降低血压,抗过敏、除腥臭、怪味、宁心安神、益智健脑、增强食欲,红枣中还含有抑制癌细胞,甚至可使癌细胞向正常细胞转化的物质,对高血压病有防治功效具有补中益气、健脾养胃、益精强志、和五脏、通血脉、聪耳明目、止烦、止渴、止泻、缓和药性的功能。
桃仁:活血祛瘀,润肠通便,止咳平喘的功效,桃仁入药以后能活血化瘀,它能让人体血管扩张,也能增加动脉血管中的血液流量,可以预防血管阻力产生,除此以外,桃子还能抑制血液凝固具有明显溶血作用,能有效预防血栓生成,桃仁中还含有多种天然消炎成分,特别是杏仁苷的含量比较高,这种物质对人体内的多种炎症都有明显消除作用,可以让人体内多种致病菌的活性降低。另外平时人们他用桃仁以后还能提高人类身体的抗过敏能力,能减少多种过敏症状发生。
普洱茶:具有清热、消暑、暖胃、解毒、减肥、降脂、防止动脉硬化、防止冠心病、降血压、抗衰老、降血糖、抑菌消炎、减轻烟毒、减轻重金属毒、抗辐射、防龋齿、明目、助消化、抗毒、预防便秘、解酒通便、祛痰、祛风解表、止咳生津、益力气、延年益寿等功效。普洱茶对防止动脉硬化、防止冠心病、降血压、抗衰老、降血糖尤为突出。
金花茶:属无毒级、含有400多种营养物质、无毒副作用。富含茶多糖、茶多酚、总皂甙、总黄酮、茶色素、咖啡因、蛋白质、维生素B1、B2、维生素C、维生素E、叶酸、脂肪酸、B-胡萝卜素等多种天然营养成份;金花茶含有茶氨酸、苏氨酸等几十种氨基酸,以及富含有多种对人体具有重要保健作用的天然有机锗(Ge)、硒(Se)、钼(Mo)、锌(Zn)、钒(V)等微量元素,和钾(K)、钙(Ca)、镁(Mg)等宏量元素。金花茶可以活化胰岛细胞,促进胰岛素的分泌,加速血糖的分解和代谢, 金花茶含有多种营养保健元素, 可以有效的促使我们的血液呈弱碱性,从而激活免疫系统的淋巴细胞,提高和加强人体的免疫力,使得我们的抵抗能力变强,同时也可以使得糖尿病患者的病症得到一定的缓解和好转, 金花茶可以很快的排出体内的毒素,并降低体内的血糖峰值。
葛根:升阳解肌,透疹止泻,除烦止渴。治伤寒、温热头痛项强,烦热消渴,泄泻,痢疾,癍疹不透,高血压,心绞痛,耳聋。葛根素具有有明显的扩张冠状血管的作用,能使冠血流量增加,血管阻力降低,可缩小心肌梗塞范围,被认为是一种β-肾上腺素受体阻滞剂,葛根总黄酮和葛根素能减慢心率,降低心脏总外周阻力,减少心肌耗氧量;提高心肌工作效率.葛根素还能明显减少缺血引起的心肌乳酸的产生,改善梗塞心肌的代谢,葛根总葛酮和葛根素能使血浆肾素活性和血管紧张素显著降低,血压下降,葛根素对微循环障碍有明显的改善作用,主要表现为增加微血管运动的振幅和提高局部微血流量,葛根总黄酮具有明显扩张脑血管的作用,改善脑微循环和外周循环,葛根素还能改善视网膜血管末稍单位的阻滞状态,从而提高视功能。
茯苓:茯苓能利水渗湿,药性平和,利水而不伤正气,为利水渗湿要药。凡小便不利、水湿停滞的症候,不论偏于寒湿,或偏于湿热,或属于脾虚湿聚,均可配合应用。同时还具有健脾,安神的功效。主治:水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。现有用于子宫肌瘤的治疗。还对于脾虚不能运化水湿,停聚化生痰饮之症,具有治疗作用。
百合:润肺止咳,清心安神。治肺久嗽,咳唾痰血;热病后余热未清,虚烦惊悸,神志恍惚;脚气浮肿。主治:润肺止咳:用于肺燥或阴虚之咳嗽、咯血,常配川贝;清心安神:用于热性病后余热不清、虚烦不眠、神志恍惚。百合含多种生物碱,对白细胞减少症有预防作用,能升高血细胞,对化疗及放射性治疗后细胞减少症有治疗作用。百合可改善睡眠作用,可提高睡眠质量,对失眠多梦有着不错的疗效,适当食用可以帮助我们更好的预防癌症,百合在体内还能促进和增强单核细胞系统和吞噬功能,提高机体的体液免疫能力,因此百合对多种癌症均有较好的防冶效果,百合还具有减轻炎症,有效止痛,对通风发作所致的急性关节炎症有辅助治疗作用。
淡竹叶:含有黄酮等成分,有增强机体免疫力,提高机体对不良环境和细菌的抵抗能力, 有抵抗自由基,有sod活性,对亚硝化反应具有很好的阻断能力,因此,具有抗氧化、抗衰老的功能,其叶绿素是绿色植物抗诱变的重要成分,因此,具有抗肿瘤、防癌变的功效;另外还有扩张动脉、增强血管弹性、清理血液垃圾的功效,能很好的改善心肌缺血,对心脏缺血和脑缺血有一定的保护作用。
山楂:有很好的活血破血功效,可以促进血液中的垃圾排除,加快身体的新陈代谢性微温酸,入脾、胃、肝经;具有消食健胃,活血化瘀,驱虫之功效;能防治心血管疾病,具有扩张血管、增加冠脉血流量、改善心脏活力、兴奋中枢神经系统、降低血压和胆固醇、软化血管及利尿和镇静作用;还有强心作用,对老年性心脏病也有益处;山楂所含的黄酮类和维生素C、胡萝卜素等物质能阻断并减少自由基的生成,山楂中还有平喘化痰、抑制细菌、治疗腹痛腹泻的成分,能增强机体的免疫力,有防衰老、抗癌的作用。
枸杞子:具有生理活性,能够增强非特异性免疫功能,提高抗病能力,抑制肿瘤生长和细胞突变,能明显提高吞噬细胞的吞噬功能,提高淋巴细胞的增殖能力,有抗衰老作用;枸杞子通过神经--内分泌--免疫调节网络发挥抗癌作用;作为辅助药物来配合放疗等抗肿瘤治疗,减轻放疗的毒副作用,提高疗效,保护机体的免疫功能;枸杞子能有效降低患高脂血症、血清中甘油三酯和胆固醇的含量,具有降血脂、调节脂类代谢功能,对预防心血管疾病具有积极作用;枸杞多糖能明显增强受损胰岛细胞内超氧化物歧化酶(SOD)的活性,提高胰岛细胞的抗氧化能力,减轻过氧化物对细胞的损伤,降低内二醛生成量,这表明枸杞多糖对胰岛细胞有一定的保护作用;枸杞多糖可降低血浆及血管中丙二醛、内皮素含量,增加降钙素基因相关肽的释放,防止高血压形成;枸杞富含胡萝卜素,在人体内能转化成维生素A,具有维持上皮组织正常生长与分化的功能,量充足时可预防鼻、咽、喉和其他呼吸道感染,提高呼吸道抗病能力;还具有抗脂肪肝枸杞中所含的甜菜碱有抑制脂肪在肝细胞内沉积、促进肝细胞新生的作用。同时可防止四氯化碳引起的肝功能紊乱,故而构杞具有明确的保护肝脏、抗脂肪肝的功效。
仙草:内含黄酮类物质、多糖、香精素、微量元素以及维生素,具有抑制癌症细胞生长、降低血压的作用;具有增强和提高机体免疫机能作用;香精素有镇静、清凉解毒利水的功效;微量元素具有抑制自由基形成、抗衰老、抗癌的作用;维生素能调节和增强生理机能等,仙草主治中暑、热毒、消渴、高血压、肾脏病、糖尿病、关节肌肉疼痛、淋病、急性风湿性关节炎、感冒、黄疸,急性肾炎、泄泻、痢疾等。
决明子:具有明目、通便、清肠,可治肝火或肝阳头痛眩晕,还可以用来治疗高血压,抑制血清胆固醇升高和动脉粥样硬化斑块形成的作用,可用来治疗高血脂症、脂肪肝等,另外,对咽喉热痛、风热感冒等症状能起到一定的预防和治疗作用。
白芷:具有祛风湿,活血排脓,生肌止痛。用于头痛、牙痛、鼻渊、肠风痔漏、赤白带下、痈疽疮疡、皮肤瘙痒的功效。可以祛风,燥湿,消肿,止痛,可以治疗头痛、骨痛、牙痛、腹痛、皮肤燥痒等问题,白芷里面有大量的异欧前胡素和印度榅桲,能够起到降血压作用。另外,还具有对大肠杆菌、痢疾杆菌、变形杆菌、伤寒杆菌、副伤寒杆菌、绿脓杆菌、霍乱弧菌、人型结核杆菌等均有抑制作用,具有抗菌、抗炎之功效;白芷中含的异欧前胡素和印度榅桲素具有降血压的作用,也具有抗癌作用。
甘草:具有补脾益气、缓解止痛、祛痰止咳、清热解毒、调和某些药物的烈性之功效,用于治疗用于心气虚,心悸怔忡,脉结代,以及脾胃气虚,倦怠乏力等;治疗胃痛、腹痛及腓肠肌挛急疼痛等,用于止咳化痰作用,用于气管炎,肺气肿的病引起的咳嗽痰多,气喘,黏痰不易排出等症的治疗,用于痈疽疮疡、咽喉肿痛,湿毒,有抗菌消炎作用。
所述治疗高尿酸血症痛风脂肪肝高脂血症的药物制备方法,制作时利用的设备包括超声波提取锅、管道离心机14以及冷冻干燥机18、双效真空浓缩器16设备,这些设备均采用目前市场上现有的设备,在表1中的实施例是按照以下药物制备步骤实施的:
1)根据超声波提取锅的处理量,按照大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12的重量比分别称取上述药材重量,在本实施例中,每次所用药物原材料为20公斤,按照上述重量比进行各种药材称取,总重量为20公斤;
在本实施例中,利用了一般的电子称11分别进行了各种药材的承重;
2) 将以上药材筛选干净放入超声波提取锅内,在超声波提取锅内加入10倍于药物的水,
在本实施例中,利用了振动筛12对原材料进行筛选,所述超声波提取锅利用了热回流机组13,利用其中设置的超声波进行萃取;
3)提取时,超声波提取锅控温50-65℃,在常压下超声波提取两次,每次超声波提取时间为120分钟,在本实施例中,分别利用50℃、60℃、65℃的温度进行了加热萃取;
4)利用管道离心机14过滤去渣,在本实施例中利用了双联过滤设备对萃取液进行了过滤处理;
5)提取液用双效真空浓缩器16在低温真空浓缩成稠膏;
在本实施例中,首先将萃取的药液储存在储液罐15中,然后利用双效真空浓缩器16进行低温真空浓缩,在本实施例中利用了球形浓缩器QN-300进行了低温真空浓缩;
6)利用冷冻干燥机18在-40℃的温度下,将浓缩稠膏降温,冷冻成干膏,在本实施例中,首先利用真空干燥机17进行改造,然后利用冷冻干燥机18处理;
7)将干膏粉碎成80目细粉,在本实施例中,利用了粉碎机19粉碎至80目,粉碎机中使用的筛子为80目的过滤筛;
8)将细粉制作成多种形态的药物。
所述多种形态包括固体饮料、饼干、袋泡茶、液体饮料、泡腾片或胶囊等。
所述压片糖果、茶膏、袋泡茶、胶囊内为纯中药萃取物。
所述固体饮料、饼干中均匀混合有辅料,所述辅料麦芽糊精,麦芽糊精与干膏细粉的重量比为1:1,其中含有的干膏细粉重量为1g。
所述泡腾片中,中药萃取物干膏细粉占40%,柠檬酸25%,碳酸氢钠35%,一个泡腾片中含有的干膏细粉重量为1g。
所述液体饮料内添加有10倍于干膏细粉重量的饮用水,每瓶内含有干膏细粉重量为1g。
进一步,所述固体饮料、饼干、袋泡茶、液体饮料、胶囊的最小包装中含有的干膏细粉相同,在本实施例中最小包装内含有的干膏细粉重量为1g。1g干膏细粉内药性相当于12g生药材的药性。
服用方法:
上述压片糖果或固体饮料、液体饮料、茶膏、袋泡茶、饼干、泡腾片、胶囊口服,每次1~2g,每日1~3次。
服用时,可根据上述范围,结合病情、体质、年龄适当调节服用膏细粉重量和服用次数。
本药品孕妇禁用。
实施例:
表1 本发明的实施例表
备注1:上述实施例1-2使用萃取温度为50℃,实施例3-4使用萃取温度为60℃,实施例5-6使用萃取温度为60℃,其他参数均相同,每次药材总重量为20公斤;
备注2:每个实施例中,均分为固体饮料、饼干、袋泡茶、液体饮料、胶囊、泡腾片、饮料的服用者,人数基本相等。
在制备过程中,通过利用超声波萃取,能够利用物理作用、溶剂和样品之间空化作用能促使植物细胞组织破壁或变形,溶质的质点间的振动、加速度冲击、声压剪切等效应力加强,使物料形成局部点的极端高温高压使大体积的中药材可充分接触到超声波探头,加速原料药内有效成分的均匀析出,提高目标物从固相转移到液相的传质速率;在50℃-65℃水温超声波强化萃取,无水煮高温,不破坏中药材中某些具有热不稳定,易水解或氧化特性的药效成份。
通过服用这种中药,能够补中益气,健脾养胃、益精强志、活血化瘀、扩张血管,进而提高血管中的血流量,增强血管弹性、清理血液垃圾,减轻体内重金属毒素,提高身体抗过敏能力、增强人体器官功能,增强抵抗各种病毒的能力,提高了自身免疫能力,降低了血管血流阻力,提高了心肌工作效率,提高了抑制血液凝固功效,改善了患者的脑微循环和外周循环,降低血浆中的尿酸钠含量,降低血清总胆固醇、LDL胆固醇浓度、降低血清三酰甘油,防止动脉粥样硬化,能抑制脂肪在肝细胞内沉积、促进肝细胞新生的作用,可降低高脂血症引发的心脑血管引起的疾病以及糖尿病、高血压、脂肪肝等的疾病,避免突发性中风、心肌梗死、心脏猝死等发生,延长寿命。
Claims (8)
1.治疗高尿酸血症痛风脂肪肝高脂血症的药物 ,其特征在于:所述药物原料包括大枣、桃仁、普洱茶、金花茶、葛根、茯苓、百合、淡竹叶、山楂、枸杞子、仙草、决明子、白芷、甘草,大枣与其他药物的重量比为:大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12。
2.治疗高尿酸血症痛风脂肪肝高脂血症药物的制备方法,包括超声波提取锅、管道离心机以及冷冻干燥机、双效真空浓缩器设备,其特征在于,所述制备方法包括以下步骤:
1)根据超声波提取锅的处理量,按照大枣:桃仁:普洱茶:金花茶:葛根:茯苓:百合:淡竹叶:山楂:枸杞子:仙草:决明子:白芷:甘草=100:90~110:8~12: 8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12:8~12的重量比分别称取上述药物原料重量;
2) 将以上药物原料筛选干净放入超声波提取锅内,在超声波提取锅内加入10倍于药物原料的水;
3)提取时,超声波提取锅控温50-65℃,超声波提取两次,每次超声波提取时间为120分钟,在常压下提取;
4)利用管道离心机过滤去渣;
5)提取液用双效真空浓缩器在低温真空浓缩成稠膏;
6)利用冷冻干燥机在-40℃的温度下,将浓缩稠膏降温,冷冻成干膏;
7)将干膏粉碎成80目细粉;
8)将细粉制作成多种形态的药物。
3.根据权利要求2所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述多种形态包括固体饮料、饼干、袋泡茶、液体饮料、泡腾片或胶囊。
4.根据权利要求3所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述压片糖果、茶膏、袋泡茶、胶囊内为纯中药萃取物。
5.根据权利要求3所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述固体饮料、饼干中均匀混合有辅料,所述辅料麦芽糊精,麦芽糊精与干膏细粉的重量比为1:1。
6.根据权利要求3所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述泡腾片中,中药萃取物干膏细粉占40%,柠檬酸25%,碳酸氢钠35%。
7.根据权利要求3所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述液体饮料内添加有10倍于干膏细粉重量的饮用水。
8.根据权利要求3所述的所述的治疗高尿酸血症痛风脂肪肝高脂血症药物,其特征在于:所述固体饮料、饼干、袋泡茶、液体饮料、泡腾片或胶囊的最小包装中含有的干膏细粉相同。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910197313.3A CN109700944A (zh) | 2019-03-15 | 2019-03-15 | 治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910197313.3A CN109700944A (zh) | 2019-03-15 | 2019-03-15 | 治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109700944A true CN109700944A (zh) | 2019-05-03 |
Family
ID=66266887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910197313.3A Pending CN109700944A (zh) | 2019-03-15 | 2019-03-15 | 治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109700944A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934963A (zh) * | 2019-12-26 | 2020-03-31 | 张冬 | 一种降尿酸组合物及其制备方法、口服药剂和应用 |
CN112294925A (zh) * | 2020-12-08 | 2021-02-02 | 恒慈堂健康管理(河南)有限责任公司 | 一种用于治疗痛风、胃病、便秘的药物及其制备方法 |
CN112826844A (zh) * | 2021-03-10 | 2021-05-25 | 海南普圣医药科技有限公司 | 用于根治痛风的中药丸剂及其制备方法 |
CN113018399A (zh) * | 2021-03-25 | 2021-06-25 | 河南乾坤道医药有限公司 | 一种治疗历节风、痛风、骨节疼痛的中草药产品 |
CN115702686A (zh) * | 2021-08-16 | 2023-02-17 | 吉林省均泰东方药业有限公司 | 一种林蛙(雪蛤)卵饮品的制备方法 |
CN116173149A (zh) * | 2023-03-24 | 2023-05-30 | 深圳万久投资发展有限公司 | 一种可调理人体代谢的植物饮料及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264215A (zh) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | 一种治疗急慢性痛风性关节炎的药物组合及其制备方法 |
CN101683462A (zh) * | 2008-09-23 | 2010-03-31 | 天津市中宝制药有限公司 | 一种疏肝补肾中药组合物 |
CN102552579A (zh) * | 2012-01-21 | 2012-07-11 | 北京亚东生物制药有限公司 | 一种治疗高血脂症性脂肪肝的中药组合物、其制备方法和质量检测方法及应用 |
CN104642654A (zh) * | 2014-12-30 | 2015-05-27 | 韩超央 | 一种控制体重并降低尿酸降三高保健茶 |
CN105343658A (zh) * | 2015-11-02 | 2016-02-24 | 刘长波 | 一种治疗高尿酸合并高脂血症的扶正降浊方 |
CN107303383A (zh) * | 2016-04-21 | 2017-10-31 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
-
2019
- 2019-03-15 CN CN201910197313.3A patent/CN109700944A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264215A (zh) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | 一种治疗急慢性痛风性关节炎的药物组合及其制备方法 |
CN101683462A (zh) * | 2008-09-23 | 2010-03-31 | 天津市中宝制药有限公司 | 一种疏肝补肾中药组合物 |
CN102552579A (zh) * | 2012-01-21 | 2012-07-11 | 北京亚东生物制药有限公司 | 一种治疗高血脂症性脂肪肝的中药组合物、其制备方法和质量检测方法及应用 |
CN104642654A (zh) * | 2014-12-30 | 2015-05-27 | 韩超央 | 一种控制体重并降低尿酸降三高保健茶 |
CN105343658A (zh) * | 2015-11-02 | 2016-02-24 | 刘长波 | 一种治疗高尿酸合并高脂血症的扶正降浊方 |
CN107303383A (zh) * | 2016-04-21 | 2017-10-31 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
Non-Patent Citations (7)
Title |
---|
国家药典委员会著: "《中华人民共和国药典临床用药须知 中药饮片卷 2015年版》", 30 September 2017, 中国医药科技出版社 * |
广西林业科学研究院: "《广西林下主要经济植物栽培》", 30 June 2013, 广西科学技术出版社 * |
张顺高等: "《云南茶叶系统生态学》", 30 June 2017, 云南科技出版社 * |
李佐法等: "《现代内科药物治疗学》", 31 December 2008, 天津科学技术出版社 * |
李梅等: "《中医药学基础》", 31 January 2016, 中国医药科技出版社 * |
梅全喜等: "《现代中药药理与临床应用手册 第3版》", 31 October 2016, 中国中医药出版社 * |
苏小军等: "《新编中医内科学》", 30 June 2018, 上海交通大学出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934963A (zh) * | 2019-12-26 | 2020-03-31 | 张冬 | 一种降尿酸组合物及其制备方法、口服药剂和应用 |
CN112294925A (zh) * | 2020-12-08 | 2021-02-02 | 恒慈堂健康管理(河南)有限责任公司 | 一种用于治疗痛风、胃病、便秘的药物及其制备方法 |
CN112826844A (zh) * | 2021-03-10 | 2021-05-25 | 海南普圣医药科技有限公司 | 用于根治痛风的中药丸剂及其制备方法 |
CN113018399A (zh) * | 2021-03-25 | 2021-06-25 | 河南乾坤道医药有限公司 | 一种治疗历节风、痛风、骨节疼痛的中草药产品 |
CN115702686A (zh) * | 2021-08-16 | 2023-02-17 | 吉林省均泰东方药业有限公司 | 一种林蛙(雪蛤)卵饮品的制备方法 |
CN116173149A (zh) * | 2023-03-24 | 2023-05-30 | 深圳万久投资发展有限公司 | 一种可调理人体代谢的植物饮料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109700944A (zh) | 治疗高尿酸血症痛风脂肪肝高脂血症的药物及其制备方法 | |
CN105265990A (zh) | 一种铁皮石斛复方保健酵素饮品及其制备方法 | |
CN107029146A (zh) | 一种清肺化痰补气健脾养肺的中药组合物及其制备方法 | |
CN106135891A (zh) | 一种对酒精性肝损伤具有保护功能的保健食品 | |
CN101658618B (zh) | 一种解酒护肝复方制剂及应用 | |
CN109528807A (zh) | 一种增强人体免疫力的中药组合物及其制备方法和应用 | |
CN117599140A (zh) | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 | |
CN101167846A (zh) | 一种具有降糖作用的胶囊及其制备方法 | |
CN105724696A (zh) | 一种提神罗汉果茶 | |
CN109820943A (zh) | 一种治疗痛风的壮药制剂及其制备方法 | |
CN104757536A (zh) | 恰玛古保健品 | |
CN105875913A (zh) | 一种红景天茶及其制备方法 | |
CN105999058B (zh) | 鬼针草降脂片 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
CN102846720B (zh) | 一种降血脂、提高缺氧耐受力的组合物 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN112294925A (zh) | 一种用于治疗痛风、胃病、便秘的药物及其制备方法 | |
CN110051791A (zh) | 一种预防和治疗呼吸系统疾病中药组合物及其制备方法 | |
CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
CN107737292B (zh) | 治疗老年人夜尿症的中药制剂及其制备方法 | |
CN106615362A (zh) | 一种糖尿病人专用保健茶及其制备方法 | |
CN108478701A (zh) | 一种增强免疫力的含片 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN101164595A (zh) | 一种治疗厌食症的中药 | |
CN105521335A (zh) | 一种治疗阵发性室上性心动过速的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190503 |